Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra dose-ranging study in moderate-to-severe traumatic brain injury
2016-004974-16Phase 2Terminated
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Jun 2019
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in traumatic brain injury (TBI) comparing Kineret dose-ranging arm(s) with Placebo (2 arms). Primary endpoint: Dose-dependent difference in cerebral cytokine concentrations after 48 hours of IMP administration. Started Jun 2019; status: terminated.
02
Drugs
anakinra
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on 2016-004974-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004974-16.